ClinicalTrials.gg
CompletedNCT07546903Updated Nov 4, 2026

Comparison of Analgesic Efficacy of Suprainguinal Fascia Iliaca and Quadro-iliac Blocks in Hip Fracture Surgery

An interventional study of Suprainguinal Fascia Iliaca Block and Quadro-Iliac Plane Block in Post Operative Pain, sponsored by Hitit University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Hitit University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now CompletedPrimary outcomes revised+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Pain, Postoperative by Hitit University — 4 open to participants now, 4 under way, none of them phase 3. Pain, Postoperative · Hitit University.

Enrollment
2nd of 10
85 · median 74
Started
2026
with 3 others
No phase
10 of 10
4 open now
Registered
5th of 10
by date

Among the 10 studies in Pain, Postoperative by Hitit University, this one is the 2nd largest by enrollment, is one of 4 that started in 2026, is one of 10 with no phase, and was the 5th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

4 of the 10 studies in Pain, Postoperative by Hitit University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pain, Postoperative by Hitit University, or all of them as a file.
02

Study summary

This prospective, randomized, double-masked trial compared two ultrasound-guided regional analgesic techniques, suprainguinal fascia iliaca block (SIFI) and quadro-iliac plane block (QIPB), in adults undergoing surgery for hip fracture under spinal anesthesia. The primary outcome was total opioid consumption, expressed as approximate intravenous morphine equivalents, during the first 24 hours after complete resolution of spinal motor block (Bromage score 0). Secondary outcomes included pain at rest and during movement assessed using a 0-10 numeric rating scale, rescue analgesic requirements, nausea and vomiting, quality of recovery, time to first assisted standing and other recovery measures, and patient satisfaction. Both groups received the same postoperative multimodal analgesic regimen. Eighty-five participants were randomized, and 70 participants completed follow-up and were included in the reported analysis.

Read the detailed description

This prospective, parallel-group randomized trial compared two ultrasound-guided blocks in adults undergoing hip fracture surgery under spinal anesthesia. Participants and postoperative outcome assessors were masked; the anesthesiologist performing the block knew the assigned technique. Eighty-five participants were randomized (43 SIFI and 42 QIPB), and 35 per group were included in the reported analysis after post-randomization exclusions. Different surgical procedures for hip fracture were included; procedure type was not used for subgroup analysis.

Both blocks were performed before spinal anesthesia using a linear ultrasound probe and an 80-mm peripheral block needle. SIFI was performed supine, with injection deep to fascia iliaca over the iliacus muscle and suprainguinal spread. QIPB targeted the fascial plane related to the posterior surface of quadratus lumborum at its attachment to the iliac crest. QIPB was performed prone, or in lateral decubitus when pain prevented tolerance of prone positioning. Both blocks used 40 mL of 0.25% bupivacaine (100 mg). The peripheral block dose limit was 2 mg/kg; no dose reduction was required. Spinal anesthesia used 12.5 mg of 0.5% hyperbaric bupivacaine.

Both groups received intravenous paracetamol 1 g every eight hours and tramadol patient-controlled analgesia (10-mg bolus, 20-minute lockout, no background infusion, maximum 400 mg per day). Rescue analgesia was 25 micrograms of intravenous fentanyl if either rest or movement pain exceeded 4 on the numeric rating scale. Rescue doses were recorded separately from patient-controlled analgesia button presses. Pain was reassessed at the next scheduled assessment, with further rescue analgesia when required.

Time zero was complete resolution of spinal motor block (Bromage score 0). Rest and movement pain were assessed at 0, 1, 3, 6, 12, 18 and 24 hours from time zero. Movement was defined as changing from a lying to a sitting position. Opioid consumption and rescue analgesia were assessed within the same 24-hour window. Tramadol and fentanyl doses were recorded separately and summarized as approximate intravenous morphine equivalents. The Turkish QoR-15 was administered before surgery and 24 hours after time zero; higher scores indicate better recovery. First assisted standing, first oral intake and first passage of either flatus or stool were timed from time zero. Satisfaction was rated from 1 to 10.

The first participant was enrolled on May 4, 2026. Final primary outcome assessments and all study follow-up were completed on September 13, 2026.

The difference in outcome priority between the protocol and the initial registry version was reconciled after study completion by adopting the protocol hierarchy.

03

Conditions studied

  • Post Operative Pain

Keywords

  • Hip Fracture
  • Suprainguinal Fascia Iliaca Block
  • Quadro-Iliac Plane Block
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for surgical treatment of hip fracture
  • Age 18 years or older
  • I-III
  • Hemodynamically stable
  • Conscious and able to communicate verbally
  • (BMI) ≤35 kg/m²
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • IV-V or hemodynamic instability
  • Infection at the block site
  • Allergy to local anesthetics or tramadol
  • Neuromuscular or peripheral nerve disease
  • Chronic pain
  • Coagulopathy or anticoagulant treatment
  • High-dose opioid use within the preceding three days
  • Severe hepatic or renal insufficiency
  • Diabetes mellitus
  • Pregnancy or breastfeeding
  • Inability to understand or respond to NRS or QoR-15 assessments
  • Inability to communicate in Turkish
  • Previous hip surgery

Criteria for withdrawal after enrollment:

  • Surgery not completed as planned or terminated before completion
  • NRS >7 for four consecutive hours despite the planned multimodal analgesia regimen
  • Inability to perform postoperative NRS assessments
  • Inability to use patient-controlled analgesia because of technical problems
  • Postoperative hemodynamic deterioration or other health problems preventing completion of follow-up
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Active comparator
    Suprainguinal Fascia Iliaca Block (Group S)

    Before spinal anesthesia, participants received ultrasound-guided suprainguinal fascia iliaca block in the supine position. A sterile-covered linear probe and an 80-mm peripheral block needle were used. The needle was advanced in-plane to the space deep to fascia iliaca and superficial to iliacus, proximal to the inguinal ligament. After hydrodissection with 2 mL saline, 40 mL of 0.25% bupivacaine (100 mg) was injected while observing spread in the fascial plane. Both groups received the same spinal anesthesia and postoperative multimodal analgesic regimen.

    Procedure: Suprainguinal Fascia Iliaca Block

  • Experimental
    Quadro-Iliac Plane Block (Group Q)

    Before spinal anesthesia, participants received ultrasound-guided quadro-iliac plane block. The patient was prone, or in lateral decubitus when pain prevented tolerance of the prone position. A sterile-covered linear probe and an 80-mm peripheral block needle were used. Ultrasound orientation identified quadratus lumborum and its attachment to the iliac crest. The needle targeted the fascial plane related to the posterior surface of quadratus lumborum at this level. After hydrodissection, 40 mL of 0.25% bupivacaine (100 mg) was injected with ultrasound observation of fascial plane spread. Both groups received the same spinal anesthesia and postoperative multimodal analgesic regimen.

    Procedure: Quadro-Iliac Plane Block

Interventions

  • ProcedureSuprainguinal Fascia Iliaca Block

    the area between the iliacus muscle and the fascia iliaca will be reached at the level of the anterior superior iliac spine, proximal to the inguinal ligament. Hydrodissection will be performed with 2 mL of saline, followed by the injection of 40 mL of 0.25% bupivacaine.

  • ProcedureQuadro-Iliac Plane Block

    Ultrasound-guided injection of 40 mL 0.25% bupivacaine (100 mg) into the fascial plane related to the posterior surface of quadratus lumborum at its attachment to the iliac crest, before spinal anesthesia. A linear probe and an 80-mm peripheral block needle were used. Patients were prone or, when pain prevented tolerance of prone positioning, in lateral decubitus.

06

What researchers measure

Primary outcomes

  1. Total opioid consumption during the first 24 hours after Bromage score 0

    Total tramadol delivered by intravenous patient-controlled analgesia and intravenous fentanyl administered as rescue analgesia were recorded separately. Approximate intravenous morphine equivalents (mg) were calculated as 0.1 × tramadol (mg) + fentanyl (micrograms)/15. Premedication fentanyl was excluded.

    Time frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)

Secondary outcomes

  1. Pain at rest and during movement assessed by the Numeric Rating Scale (NRS)

    Rest and movement pain were assessed separately using an 11-point numeric rating scale: 0 indicates no pain and 10 the worst imaginable pain. Movement was defined as changing from a lying to a sitting position. Time zero was complete resolution of spinal motor block (Bromage score 0). Both pain series during the first 24 hours were secondary outcomes.

    Time frame: 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0)

  2. Rescue analgesia requirement

    Number of participants receiving at least one rescue analgesic dose. Rescue analgesia was 25 micrograms intravenous fentanyl when either rest or movement NRS exceeded 4. Patient-controlled analgesia button presses were not classified as rescue analgesia.

    Time frame: First 24 hours after Bromage score 0

  3. Time to first rescue analgesia

    Time in minutes from Bromage score 0 to the first intravenous rescue fentanyl administration. Participants without rescue analgesia were censored at 24 hours for time-to-event analysis.

    Time frame: Up to 24 hours after Bromage score 0

  4. Postoperative nausea and vomiting

    Nausea and vomiting were scored at each assessment on the study scale: 1, no nausea or vomiting; 2, nausea without vomiting; 3, one episode of vomiting or persistent nausea; 4, two or more vomiting episodes within four hours. Higher scores indicate worse symptoms. Ondansetron use and total dose were also recorded.

    Time frame: 0, 1, 3, 6, 12, 18 and 24 hours after Bromage score 0

  5. Quality of recovery assessed by QoR-15

    The Turkish Quality of Recovery-15 questionnaire was administered before and after surgery. Total scores range from 0 to 150, with higher scores indicating better recovery. The A section contains the first 10 positive items (0-100); the B section contains the last five negative symptom items (0-50), scored so that higher values mean fewer symptoms.

    Time frame: Preoperatively on the morning of surgery and 24 hours after Bromage score 0

  6. Time to first assisted standing

    Time in hours from Bromage score 0 until the participant first stood with assistance. Follow-up continued to the first event even when it occurred after 24 hours.

    Time frame: From complete resolution of spinal motor block (Bromage score 0) until first assisted standing during postoperative inpatient follow-up, an average of approximately 26 hours among assessed participants.

  7. Time to first oral intake

    Time in hours from complete resolution of spinal motor block (Bromage score 0) to first oral intake during the following 24 hours.

    Time frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)

  8. First passage of flatus or stool

    Time in hours from complete resolution of spinal motor block (Bromage score 0) to whichever occurred first: passage of flatus or stool, during the following 24 hours. Participants without an event were observed for the full 24-hour period and classified as having no event within 24 hours. Event times were not assigned a zero duration.

    Time frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)

  9. Patient satisfaction

    At 24 hours after complete resolution of spinal motor block (Bromage score 0), participants rated satisfaction with the treatment from 1 to 10. Higher scores indicate greater satisfaction.

    Time frame: 24 hours after complete resolution of spinal motor block (Bromage score 0)

07

Study locations

1 site
  • Hitit university
    Merkez, Çorum 19100, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Our regulations forbid to share the IPD

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2026 to primary completion in Sep 2026, 4 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 4 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Oct 2025 → May 2026, primary completion Apr 2026 → Sep 2026 and completion Jun 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 23, 2026
StartActual
May 4, 2026was Oct 2025
Primary completionActual
Sep 13, 2026was Apr 2026
CompletionActual
Sep 13, 2026was Jun 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Hitit university · Merkez, Turkey (Türkiye)
Show 1 removed
  • Hitit university · Çorum, Turkey (Türkiye)
Oct 30, 2026
Start date
Oct 20, 2025→May 4, 2026
Oct 30, 2026
Primary completion
Apr 30, 2026→Sep 13, 2026 (actual)
Oct 30, 2026
Study completion
Jun 15, 2026→Sep 13, 2026 (actual)
Oct 30, 2026
Enrollment
70 (estimated)→85 (actual)
Oct 30, 2026
Eligibility
2 inclusion criteria edited, 1 added; 9 exclusion criteria edited, 5 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedPatients agedAge 18 years andor older
  • EditedHemodynamically stable patients
  • AddedConscious and able to communicate verbally
Exclusion criteria
  • EditedASA physical status IV-V or hemodynamic instability
  • RemovedHemodynamically unstable patients
  • EditedHistory of allergyAllergy to local anesthetics or tramadol
  • EditedPresence of neuromuscularNeuromuscular or peripheral nerve diseasesdisease
  • EditedChronic pain conditions
  • EditedCoagulopathy or ongoing anticoagulant therapytreatment
  • EditedHigh-dose opioid use within the last 3preceding three days
  • EditedInability to understand or use assessment tools (e.g.,respond to NRS, or QoR-15) assessments
  • RemovedInability to use PCA device due to technical reasons
  • AddedPrevious hip surgery
  • AddedCriteria for withdrawal after enrollment:
  • EditedSurgery not completed as planned or terminated before completion
  • EditedNRS score >7 for four consecutive hours despite the planned multimodal analgesia regimen
  • AddedInability to perform postoperative NRS assessments
  • AddedInability to use patient-controlled analgesia because of technical problems
  • AddedPostoperative hemodynamic deterioration or other health problems preventing completion of follow-up
Oct 30, 2026
Primary outcomes
Revised in 2 updates
What changed on Oct 30, 2026
  • EditedPostoperative Pain Assessedat rest and during movement assessed by the Numeric Rating Scale (NRS)Time frame: 24 hours postoperatively → 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0)
What changed on Nov 4, 2026
  • ChangedBefore Pain at rest and during movement assessed by the Numeric Rating Scale (NRS)Now Total opioid consumption during the first 24 hours after Bromage score 0Time frame: 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0) → First 24 hours after complete resolution of spinal motor block (Bromage score 0)
across 2 updates, Oct 30, 2026 – Nov 4, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 30, 2026
  • AddedTotal postoperative opioid consumptionTime frame: First 24 hours after Bromage score 0
  • AddedRescue analgesia requirementTime frame: First 24 hours after Bromage score 0
  • AddedTime to first rescue analgesiaTime frame: Up to 24 hours after Bromage score 0
  • AddedPostoperative nausea and vomitingTime frame: 0, 1, 3, 6, 12, 18 and 24 hours after Bromage score 0
  • AddedQuality of recovery assessed by QoR-15Time frame: Preoperatively on the morning of surgery and 24 hours after Bromage score 0
  • AddedTime to first assisted standingTime frame: From complete resolution of spinal motor block (Bromage score 0) until first assisted standing during postoperative inpatient follow-up, an average of approximately 26 hours among assessed participants.
  • AddedTime to first oral intakeTime frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)
  • AddedFirst passage of flatus or stoolTime frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)
  • AddedPatient satisfactionTime frame: 24 hours after complete resolution of spinal motor block (Bromage score 0)
What changed on Nov 4, 2026
  • ChangedBefore Total postoperative opioid consumptionNow Pain at rest and during movement assessed by the Numeric Rating Scale (NRS)Time frame: First 24 hours after Bromage score 0 → 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0)
across 2 updates, Oct 30, 2026 – Nov 4, 2026
Design
Study type Observational→Interventional
Oct 30, 2026
Show all 2 updates
  1. Nov 4, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Pain at rest and during movement assessed by the Numeric Rating Scale (NRS)Now Total opioid consumption during the first 24 hours after Bromage score 0Time frame: 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0) → First 24 hours after complete resolution of spinal motor block (Bromage score 0)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Total postoperative opioid consumptionNow Pain at rest and during movement assessed by the Numeric Rating Scale (NRS)Time frame: First 24 hours after Bromage score 0 → 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0)
    + 1 other change: description
  2. Oct 30, 2026
    Recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Hitit university · Merkez, Turkey (Türkiye)
    Show 1 removed
    • Hitit university · Çorum, Turkey (Türkiye)
    Start date Oct 20, 2025→May 4, 2026
    Primary completion Apr 30, 2026→Sep 13, 2026 (now actual)
    Study completion Jun 15, 2026→Sep 13, 2026 (now actual)
    Enrollment 70 (estimated)→85 (actual)
    Eligibility 2 inclusion criteria edited, 1 added; 9 exclusion criteria edited, 5 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedPatients agedAge 18 years andor older
    • EditedHemodynamically stable patients
    • AddedConscious and able to communicate verbally
    Exclusion criteria
    • EditedASA physical status IV-V or hemodynamic instability
    • RemovedHemodynamically unstable patients
    • EditedHistory of allergyAllergy to local anesthetics or tramadol
    • EditedPresence of neuromuscularNeuromuscular or peripheral nerve diseasesdisease
    • EditedChronic pain conditions
    • EditedCoagulopathy or ongoing anticoagulant therapytreatment
    • EditedHigh-dose opioid use within the last 3preceding three days
    • EditedInability to understand or use assessment tools (e.g.,respond to NRS, or QoR-15) assessments
    • RemovedInability to use PCA device due to technical reasons
    • AddedPrevious hip surgery
    • AddedCriteria for withdrawal after enrollment:
    • EditedSurgery not completed as planned or terminated before completion
    • EditedNRS score >7 for four consecutive hours despite the planned multimodal analgesia regimen
    • AddedInability to perform postoperative NRS assessments
    • AddedInability to use patient-controlled analgesia because of technical problems
    • AddedPostoperative hemodynamic deterioration or other health problems preventing completion of follow-up
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPostoperative Pain Assessedat rest and during movement assessed by the Numeric Rating Scale (NRS)Time frame: 24 hours postoperatively → 0, 1, 3, 6, 12, 18 and 24 hours after complete resolution of spinal motor block (Bromage score 0)
    Secondary outcomes 9 added
    What changed in the outcomes
    • AddedTotal postoperative opioid consumptionTime frame: First 24 hours after Bromage score 0
    • AddedRescue analgesia requirementTime frame: First 24 hours after Bromage score 0
    • AddedTime to first rescue analgesiaTime frame: Up to 24 hours after Bromage score 0
    • AddedPostoperative nausea and vomitingTime frame: 0, 1, 3, 6, 12, 18 and 24 hours after Bromage score 0
    • AddedQuality of recovery assessed by QoR-15Time frame: Preoperatively on the morning of surgery and 24 hours after Bromage score 0
    • AddedTime to first assisted standingTime frame: From complete resolution of spinal motor block (Bromage score 0) until first assisted standing during postoperative inpatient follow-up, an average of approximately 26 hours among assessed participants.
    • AddedTime to first oral intakeTime frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)
    • AddedFirst passage of flatus or stoolTime frame: First 24 hours after complete resolution of spinal motor block (Bromage score 0)
    • AddedPatient satisfactionTime frame: 24 hours after complete resolution of spinal motor block (Bromage score 0)
    Design Study type Observational→Interventional
    + 4 other changes: verification date, description, arm descriptions and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07546903
Lead sponsor
Hitit University
Responsible party
Muhammed ATICI (MD, Hitit University) — Principal investigator
First posted
Apr 23, 2026
Start date
May 4, 2026
Primary completion
Sep 13, 2026
Completion
Sep 13, 2026
Last update
Nov 4, 2026

Study contacts

Ozgur Yagan, Proffesor
study chair · Hitit University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion